January 29, 2021: Johnson & Johnson said on Friday that its one-dose coronavirus vaccine was 72% effective in the United States. Whereas the vaccine was less potent in other regions, it said.
The highly anticipated results were based on 468 confirmed Covid-19 infections among the phase three trials more than 43,000 volunteers, according to J&J.
The level of protection varied by region, J&J said, with the vaccine demonstrating 66% effectiveness overall, 72% in the United States, 66% in Latin America, and 57% in South Africa after four weeks.
“We’re proud to have reached this critical milestone, and our commitment to address this global health crisis continues with urgency for everyone, everywhere,” J&J CEO Alex Gorsky said.
The vaccine was well tolerated, with no significant safety concerns related to the immunization reported, J&J said. There were also no reports of anaphylaxis.
U.S. officials and Wall Street analysts are anticipating J&J’s vaccine’s authorization, which could happen next month.
The Food and Drug Administration has indicated it would authorize a vaccine that’s safe and at least 50% effective. According to the CDC, the flu vaccine generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated
.
If the FDA authorizes J&J’s vaccine, it would be the third approved for emergency use in the U.S. except for the Pfizer-BioNTech vaccine and Moderna’s vaccine.
J&J’s requires only one dose, which means patients will not have to come back for another dose, simplifying logistics for health-care providers. Additionally, J&J has said it plans to ship the vaccine between 2 to 8 degrees Celsius, which is about 36 to 46 degrees Fahrenheit.
In August, the Department of Health and Human Services announced that it reached a deal with Janssen, J&J’s pharmaceutical subsidiary, worth approximately $1 billion for 100 million doses of its vaccine. According to the announcement, the agreement gives the federal government the option to order an additional 200 million doses.
There are many challenges facing the painting and coating industry today, and the pandemic just added fuel to the fire. These include raw material shortages and the globalization of the painting and coating market. Other challenges include increasing regulations due to environmental concerns and increasing manufacturing costs and raw materials.
Today, most manufacturing companies face similar challenges. Those tend to intertwine themselves with implementing and adhering to best business practices. There are many reasons for this, including:
No standard definition for best practices.
The unending confusion of new shiny objects created by the technology industry.
The fact that manufacturing is such a complex industry.
Cyncly was created in September of 2022 as the new brand to unite Compusoft, 2020, and their affiliate companies after the two companies merged in 2021. One of the key factors driving the decision to form Cyncly as a global brand was that consumers worldwide wanted a seamless experience when they decided to improve their homes.
ArtiFlex Manufacturing is a premier resource for design, tooling, prototyping, automation, past model service, factory assist, and low volume tooling/production solutions. The team consists of passionate high-performance people organized in a lean fashion.
Tecnomatix® is a comprehensive portfolio of digital manufacturing solutions that helps companies to digitalize manufacturing and the process of turning innovative ideas and raw materials into transformative products. It is a software suite that enables organizations to create a digital twin of their manufacturing processes, including robots, automation, material handling systems, and people, to improve the performance of their business.
The digital asset landscape is exciting as Bitcoin blazes to a 19-month high and Galaxy Fox, a rising star in the play-to-earn gaming …